share_log

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $19

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $19

HC Wainwright & Co.維持對Relay Therapeutics的買入,將目標價下調至19美元
Benzinga ·  2023/11/08 11:02

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $33 to $19.

HC Wainwright & Co. 分析師羅伯特·伯恩斯維持Relay Therapeutics(納斯達克股票代碼:RLAY)的買入,並將目標股價從33美元下調至19美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論